Magnesium therapy in acute myocardial infarction--a double-blind study

Area of Science:

• Cardiology
• Biochemistry

Background:

• Myocardial infarction (MI) causes significant heart damage.
• Magnesium plays a crucial role in heart metabolism and function.
• Ischemic heart conditions may involve magnesium deficiency.

Purpose of the Study:

• To evaluate the effectiveness of intravenous magnesium in limiting myocardial damage during infarction.
• To investigate magnesium's role in myocardial metabolism and function in ischemic hearts.

Main Methods:

• A double-blind, randomized trial involving 76 patients.
• Administration of intravenous magnesium to the treatment group.
• Measurement of serum magnesium levels.
• Assessment of myocardial infarction size using MB-Creatine Kinase (MB-CK) release.
• Monitoring for ventricular ectopy and arrhythmias.

Main Results:

• Achieved significantly higher serum Mg++ levels in the treated group (3.6 mg/dl vs. 1.9 mg/dl).
• No significant overall reduction in infarction size (MB-CK release) in the magnesium-treated group.
• Significantly smaller infarction size observed in the subgroup without heart failure.
• A trend towards reduced ventricular ectopy in the magnesium group.
• Significantly less lidocaine usage for ventricular dysrhythmias in the magnesium-treated group.

Conclusions:

• Intravenous magnesium shows potential in limiting myocardial damage, particularly in acute coronary events without heart failure.
• Further research is warranted to explore the benefits of magnesium supplementation in managing myocardial infarction and related arrhythmias.